Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  HALO, CLDA,ZIOP

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

HALO, CLDA,ZIOP

38 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  1. [verwijderd] 11 mei 2011 14:10
    ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor

    Last update: 5/11/2011 7:30:00 AM

    - Initial Clinical Focus in Hereditary Angioedema on Optimized Subcutaneous Formulation of Cinryze® (C1 Esterase Inhibitor [Human]) - - Collaboration Provides Exclusivity until 2027 for Subcutaneous Cinryze Combination Product -

    EXTON, Pa., May 11, 2011 /PRNewswire via COMTEX/ -- ViroPharma Incorporated (VPHM) and Halozyme Therapeutics (HALO)announced today that Halozyme has granted ViroPharma an exclusive worldwide license to use Halozyme's proprietary Enhanze(TM) technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) technology in combination with a C1 esterase inhibitor. Additionally, Halozyme has agreed not to grant to any third party rights to use rHuPH20 to develop a combination product for the prevention or treatment of hereditary angioedema (HAE), or for three additional orphan disease indications.

    ViroPharma intends to apply rHuPH20 initially to develop a novel subcutaneous formulation of Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against attacks of HAE. ViroPharma seeks to combine Cinryze with rHuPH20 to enhance volume independent biodistribution, and to increase the overall convenience of the therapy by allowing for a single subcutaneous injection of Cinryze. Recently completed preclinical studies have demonstrated that rHuPH20 and Cinryze can be formulated together without compromising the activity of either agent. ViroPharma intends to initiate Phase 2 clinical testing of the combination in the second half of 2011.

    Halozyme's proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin. When injected under the skin, rHuPH20 transiently generates channels in tissues underlying the outer layers of the skin to increase the absorption and spread of injected drugs. Halozyme maintains a patent portfolio pertaining to recombinant human hyaluronidase which expires in 2027 in the U.S. and has additional patent applications that relate to recombinant human hyaluronidase and methods of using and manufacturing the enzyme that represent a barrier to entry for potential competitors looking to utilize these hyaluronidases.

    "This collaboration is consistent with our goals of continually providing innovative product enhancements, advancing long-term solutions to meet the needs of our patients, and helping to maintain and build Cinryze brand loyalty for years to come," commented Colin Broom, M.D., ViroPharma's chief scientific officer. "The goal of our broad subcutaneous Cinryze program is to enable more patients with hereditary angioedema to benefit from access to convenient formulations of Cinryze to prevent their HAE attacks."

    "We believe our rHuPH20 technology can optimize the Cinryze experience by providing an improved subcutaneous formulation of the therapy," commented Gregory I. Frost, Ph.D., Halozyme's president and chief executive officer. "We look forward to working with ViroPharma to simplify administration of this important biologic and, ultimately, provide a more convenient therapy to as many people as possible with HAE worldwide."

    Cinryze is the first and only U.S. FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a rare, debilitating and potentially fatal disease. Cinryze is currently approved for intravenous administration.

    ViroPharma / Halozyme Collaboration in Hereditary Angioedema

    Halozyme has granted ViroPharma an exclusive worldwide license to use Halozyme's proprietary Enhanze technology in combination with C1 esterase inhibitor. The initial focus of the collaboration will be on the development of a novel subcutaneous formulation of Cinryze for routine prophylaxis against attacks of HAE.

    Under the terms of the license agreement, ViroPharma will provide Halozyme an initial upfront payment of $9 million, and another $3 million on initiation of the first Phase 2 study, anticipated to begin later this year. Pending successful completion of a series of clinical, regulatory and sales milestones, ViroPharma may make further milestone payments to Halozyme which could reach up to an additional $41 million related to HAE, and up to $30 million for three additional indications. Upon regulatory approval, Halozyme will also receive a 10 percent royalty on net sales of the combination product utilizing Cinryze and rHuPH20.

    ViroPharma assumes development, manufacturing, clinical, regulatory, sales and marketing costs. Halozyme will be responsible for the supply of rHuPH20 at a price agreed to between the parties.
  2. [verwijderd] 13 mei 2011 14:11
    Ziopharm Files Investigational New Drug Application For Melanoma Treatment

    Last update: 5/13/2011 6:52:10 AM

    DOW JONES NEWSWIRES

    Ziopharm Oncology Inc. (ZIOP) submitted an investigational new drug application for a product candidate to treat melanoma under its partnership with Intrexon Corp. that was formed this year.

    Ziopharm, a small-molecule late-stage oncology drug developer, gained rights to Intrexon's entire human in vivo effector platform, including two lead clinical-stage product candidates, one which was already in early stage studies.

    Ziopharm said that data from two pre-clinical studies of the treatment in various in vivo cancer models will be presented at the annual meeting of the American Society of Gene and Cell Therapy next week in Seattle. Data from a trial of the partnership's other cancer drug candidate is set to be presented at the annual meeting of the American Society of Clinical Oncology next month in Chicago.

    Ziopharm's shares closed Thursday at $6.71 and were inactive premarket. The stock is up 44% this year.

    -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

    (END) Dow Jones Newswires

    May 13, 2011 06:52 ET (10:52 GMT)
  3. [verwijderd] 18 oktober 2011 18:24
    HALO gaat eindelijk renderen

    Vandaag 22% up.

    Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial

    Last update: 10/18/2011 1:06:00 AM

    SAN DIEGO, Oct. 18, 2011 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc. (HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required.

    "We are very pleased to see this important program achieve success in a Phase 3 pivotal clinical trial," said Gregory Frost, Ph.D., Halozyme's president and CEO. "The convenience of subcutaneous administration may provide another option for women living with early breast cancer."

    No new safety signals were observed and adverse events were overall consistent with Herceptin IV. Data from the trial will be submitted for presentation at an upcoming medical meeting and will support a marketing application to regulatory authorities in the European Union in 2012.

    Roche has additional ongoing trials of a subcutaneous formulation of MabThera® (rituximab), using Enhanze(TM) Technology in patients with CD20+ non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL).

    About the HannaH trial

    HannaH is a Phase III, open-label trial involving 596 women with HER2-positive early breast cancer. The trial was designed to compare trastuzumab concentration in the blood (pharmacokinetics), efficacy (pathologic complete response) and safety of Herceptin SC to that of Herceptin IV.

    The trial met its co-primary endpoints that were trastuzumab concentration in the blood (serum concentrations) and efficacy. Secondary endpoints included event-free survival and overall survival. In the trial the most common side effects seen were infections and abnormal blood counts (anaemia and low white blood count) similar to other trials with chemotherapy and Herceptin IV.

    About Herceptin subcutaneous delivery

    Herceptin SC uses Enhanze(TM) Technology, developed by Halozyme(R) which enables the injection of large volumes of a medication under the skin (subcutaneous) and enhances pharmacokinetics. It works by reversibly breaking down a gel-like substance (hyaluronan) that forms a barrier in the tissues between cells under the skin.

    About Breast Cancer

    Breast cancer is the most common cancer among women worldwide. Each year about 1.4 million new cases of breast cancer are diagnosed worldwide, and over 450,000 people will die of the disease annually.

    In HER2-positive breast cancer, increased quantities of the HER2 receptor are present on the surface of the tumour cells. This is known as 'HER2 positivity' and affects approximately 15-20 percent of people with breast cancer
  4. [verwijderd] 21 oktober 2011 15:31
    Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials in Patients with Type 1 and Type 2 Diabetes

    Last update: 10/21/2011 8:00:00 AM

    PH20-prandial insulin analogs achieve primary HbA1C endpoint with superior management of post-prandial glucose compared to the insulin analogs available today

    SAN DIEGO, Oct. 21, 2011 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc. (HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive results from two Phase 2 clinical trials of its ultrafast PH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to the insulin analog comparator, with superior reductions in post-prandial glucose excursions in the PH20 insulin analog arms. Compared to insulin analog alone, PH20 insulin analog use resulted in a greater than 50% increase in the proportion of patients able to consistently achieve AACE (American Association of Clinical Endocrinologists) guidelines for post-prandial glucose targets in both Type 1 and Type 2 patients. Across all of the treatment groups, there was no meaningful difference in hypoglycemia incidence or event rates. Hypoglycemia events were generally mild, and adverse events with PH20 insulin analog formulations were similar to those observed during the insulin analog comparator phase.

    "For patients living with diabetes, improved glycemic control is an important step towards maintaining good health," said Gregory Frost, Ph.D., Halozyme's president and CEO. "We are pleased to see that the combination of rHuPH20 with analog insulins enabled superior reductions in mealtime glucose swings and we look forward to presenting the full results of these studies at a medical conference in 2012."

    Study Design Overview

    Results are from two Phase 2 ultrafast insulin treatment studies, one in type 1 diabetes patients and one in type 2 patients, that compared two ultrafast insulin analog products formulated with rHuPH20 (Lispro-PH20 or Aspart-PH20) to an active comparator, Humalog (insulin lispro). More than 110 patients enrolled in each of the trials and received an insulin analog alone and one of the Analog-PH20 treatments for 12 weeks along with basal insulin glargine.

    The primary endpoint of each study was a comparison of glycemic control, the main measurement that diabetes patients use to assess treatment effectiveness, as assessed by the change in HbA1C from baseline. Data regarding post-prandial glucose levels, the proportion of patients that safely achieve HbA1C targets, rates of hypoglycemia, weight change and additional endpoints were collected as well.

    Next Steps

    The Company is planning a complete presentation of the data at a major medical meeting in 2012. Halozyme intends to explore opportunities that could maximize the global availability of its injectable PH20 insulin analog therapy to patients with Type 1 and Type 2 diabetes. The Company also has an ongoing study in patients with type 1 diabetes that use insulin pumps to determine if a single dose of rHuPH20 administered at the beginning of each subcutaneous infusion of analog insulin may reduce the variability of insulin absorption over infusion set life. It is hypothesized that more responsive and predictable insulin absorption over infusion set life may enable patients to further reduce glucose excursions on pump therapy. Results from this pre-administration feasibility pharmacokinetic and meal study will be presented next week at the Diabetes Technology Meeting (DTS) on Thursday, October 27, 2011 from 4:05 to 6:30 p.m. PDT.

    About HbA1C

    The HbA1C test is a common blood test used to diagnose type 1 and type 2 diabetes and then to gauge how well a patient's diabetes is being managed. HbA1C reflects average blood sugar level over a prolonged period of time. Specifically, the test measures the percentage of a person's hemoglobin (a protein in red blood cells that carries oxygen) that is coated with sugar (glycated). The higher the HbA1C level, the poorer one's blood sugar control and, for some diabetic patients, the higher the risk of diabetes complications.
  5. [verwijderd] 24 oktober 2011 14:44
    Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting

    Last update: 10/24/2011 8:00:00 AM

    SAN DIEGO, Oct. 24, 2011 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc. (HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, for the diabetes, cancer, dermatology and drug delivery markets, today announced its upcoming poster presentation for PEGPH20 at the 2011 EORTC-NCI-ASCO Annual Meeting, taking place October 27-29 in Brussels, Belgium. Halozyme's PEGPH20 is a PEGylated form of rHuPH20 that is being evaluated in an ongoing Phase 2 clinical trial in patients with stage IV previously untreated pancreatic cancer. The poster and abstract will also be published in the "European Journal of Cancer" proceeding book of the conference. Details of the poster session and discussion are as follows:

    Thursday, October 27, 2011

    12:00 - 8:30 p.m. CET: Targeting hyaluronan in tumor stroma. Interim translational and biomarker evaluations of pegylated hyaluronidase (PEGPH20) in patients with advanced solid tumors (discussion from 6:00 - 8)
  7. [verwijderd] 27 oktober 2011 16:00
    Halozyme Therapeutics Announces Data From Two Phase 1 Studies Of PEGPH20 Demonstrating Targeting Of Hyaluronan In Tumor Stroma

    SAN DIEGO, Oct. 27, 2011 /PRNewswire/ – Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced clinical trial results related to Halozyme’s clinical stage drug, pegylated rHuPH20 (PEGPH20). The results were presented at the 2011 EORTC-NCI-ASCO Annual Meeting on “Molecular Markers in Cancer”, taking place October 27-29 in Brussels, Belgium.

    (Logo: photos.prnewswire.com/prnh/20100302/L...

    Today’s presentation focused on translational biomarker and pharmacodynamic results from the two Phase 1 dose-finding studies in patients with advanced solid tumors that were unresponsive to prior therapies. Study 101 investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PEGPH20 as a single agent, and Study 102 investigated multiple-dosing of PEGPH20 in combination with dexamethasone.

    Results

    The pharmacodynamics of PEGPH20 were first evaluated by measuring the concentration of circulating hyaluronan (HA) catabolites. HA plasma levels increased, in a dose-dependent manner, after PEGPH20 administration. Freeing up of HA by PEGPH20 is consistent with the expected mechanism of PEGPH20.

    Tumor imaging from subsets of patients pre- and post-administration of PEGPH20 demonstrated that PEGPH20 treatment rapidly restored tumor perfusion and decreased metabolic activity in tumors. Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) showed that the imaging agent was able to access a pancreatic tumor more easily post-administration of PEGPH20. [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging showed a reduction in metabolic activity of lung metastases in a patient with metastatic rectal carcinoma after PEGPH20 treatment.

    The expected mechanism of action of PEGPH20 was further confirmed by histochemical analysis of pre- and post-treatment tumor biopsies. Biopsies of liver metastases from two patients with colorectal carcinoma were stained for HA before and after one cycle of treatment with PEGPH20. Reduced HA staining was observed in biopsies from both patients after treatment.

    “We are pleased with the results from these translational studies which provide further support to the hypothesis that PEGPH20 can favorably alter the tumor stroma of HA rich tumors,” said Joy Zhu, MD, PhD, Vice President of Oncology Clinical Development at Halozyme. ”The degradation of the protective halo of HA and normalized tumor perfusion are promising results that support our ongoing clinical trial studying PEGPH20 in combination with gemcitabine in patients with pancreatic cancer.”
  9. [verwijderd] 27 oktober 2011 19:58
    quote:

    oudje schreef op 27 oktober 2011 13:53:

    Gaat inmiddels aardig. Houdt zich na de forse stijging uitstekend.
    Gefeliciteerd, Dirk. Hoe lang zit je er al in? Zit je inmiddels ook in CHTP? Ben benieuwd.
    Hoi henk,

    Leuk je ook hier te zien, zit er v.a. gem. 7,25in.
    Volg dit aandeel vanwege Kirk Randall (xie mijn inleiding van dit draadje}
    CLDA is al overgenomen, HALO en ZIOP volgen zeker.
    Ik volg Chelsae wel noulettend, maar nog geen positie.

    Ik zag dat er een aantal oud-Crucell gedienden in AMT gedoken zijn, jammer dat dat een debacle is geworden.

    see ya,

    Dirk
  11. [verwijderd] 28 oktober 2011 13:00
    Het houdt maar niet op!!!

    Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial

    Pre-administration of rHuPH20 prior to insulin infusion provides consistent ultrafast absorption and superior post-meal glucose control

    SAN DIEGO, Oct. 27, 2011 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc.
    (NASDAQ: HALO), a biopharmaceutical company developing and commercializing
    products targeting the extracellular matrix for the diabetes, cancer,
    dermatology and drug delivery markets, today announced positive results from a
    study in patients with type 1 diabetes that receive their insulin therapy via
    pumps. The Phase 1b study was conducted as a randomized, double-blind, crossover
    design, to determine insulin pharmacokinetics, glucodynamics, safety and
    tolerability of rHuPH20 (recombinant human hyaluronidase) as a single injection
    prior to the start of three days of NovoLog® insulin aspart pump infusion
    therapy. The data demonstrated that pre-administration of 150 units of rHuPH20
    (approximately 1.3 micrograms of enzyme) led to consistent insulin exposure over
    the infusion set life and superior glucose control following meals.

    "The more consistent physiologic insulin absorption profiles observed over
    infusion set life in these studies are promising," said Daniel Einhorn, MD,
    FACP, FACE, Clinical Professor of Medicine at the University of California, San
    Diego and Medical Director of the Scripps Whittier Diabetes Institute. "Reducing
    the variability of insulin absorption should provide patients on insulin pump
    therapy improved ability to control diabetes while reducing risks of
    hypoglycemia."

    Clinical Study and Results

    The study compared pharmacokinetic (PK) and glucodynamic (GD) responses during
    euglycemic glucose clamp studies and responses to standardized mixed meal
    challenges administered in conjunction with individualized doses of insulin
    aspart, throughout the infusion set use with and without a single injection of
    rHuPH20 through the catheter set. The study also evaluated safety and local
    tolerability of rHuPH20 over the course of 72 hours of inpatient pump delivery,
    following pre-administration of rHuPH20 through subcutaneous infusion.

    Compared to insulin aspart alone, pre-administration with rHuPH20 reduced the
    variability in insulin exposure and action profiles observed with continuous
    insulin infusion and provided a consistent ultrafast profile over 3 days of use.

    Consistent with previous reports, rapid acting analog insulin delivered by
    itself via subcutaneous infusion exhibited significant variability in both
    absorption and action over three days of infusion set use. From beginning to end
    of three days of infusion, early insulin exposure varied from 15 to 27%
    (p=.0004), onset of action varied from 60 min to 30 min (p<.0001), and duration
    of action varied from 180 to 156 minutes (p<.0001).

    rHuPH20 pre-administration eliminated this variability in absorption over three
    days of infusion set use. Fractional early insulin exposure at the beginning and
    end of infusion set use was 31% and 32%, respectively (p=.76), with
    corresponding values for onset of action at 34 and 32 min (p=.73), and duration
    of action at 139 and 146 minutes (p=.28).

    rHuPH20 pre-administration also accelerated insulin absorption resulting in 57%
    more early insulin exposure (p<.0001) and a 27 minute shorter duration of action
    (p<.0001).

    In the test meal setting, the consistent ultrafast profile with
    pre-administration of rHuPH20 led to consistently reduced postprandial
    excursions.

    Reduction in 2 hour glycemic excursions (21 mg/dL) was significant (p=.017).

    Better achievement of American Association of Clinical Endocrinologists (AACE)
    target; p=.035 (7 of 15 subjects with rHuPH20 pre-treatment versus 3 of 15
    subjects without rHuPH20 were able to achieve target at all 3 dinner meals
    tested).

    Insulin aspart infusion with and without rHuPH20 pretreatment was similarly well
    tolerated.

  13. [verwijderd] 21 september 2012 15:22
    ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)

    Last update: 9/21/2012 7:00:00 AM

    EXTON, Pa. and SAN DIEGO, Sept. 21, 2012 /PRNewswire via COMTEX/ -- ViroPharma Incorporated (VPHM) and Halozyme Therapeutics, Inc. (HALO) announced today that the U.S. Food & Drug Administration (FDA) has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20. The FDA informed ViroPharma that based upon their ongoing assessment, the FDA believes the potential safety signals regarding antibodies to rHuPH20 that were detected in the clinical development program of another company's product are limited to that specific program. According to Halozyme, the detected antibodies were non-neutralizing and not associated with any clinical adverse events. The FDA has advised ViroPharma to amend the study protocol, allowing for increased laboratory sampling to monitor rHuPH20 antibody levels, and keep the Agency informed of elevated antibody levels during the treatment phase of the study.

    ViroPharma intends to provide additional commentary on next steps and timing at ViroPharma's analyst day event scheduled to begin at 9:00 A.M. E.T. today. To access the webcast of ViroPharma's analyst day, please visit .

    About Cinryze® (C1 esterase inhibitor [human])Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product. In the U.S., Cinryze is approved by the FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. In the E.U., the product is approved by the EMA for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment. Cinryze is for intravenous use only.

    Severe hypersensitivity reactions to Cinryze may occur. Thrombotic events have occurred in patients receiving Cinryze, and in patients receiving off-label high dose C1 inhibitor therapy. Monitor patients with known risk factors for thrombotic events. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.

    The most common adverse reactions in clinical trials associated with Cinryze were rash, headache, nausea, erythema, phlebitis and local reactions at the injection site. Adverse events of sinusitis and upper respiratory infection also were observed in clinical trials. No drug-related serious adverse events (SAEs) were reported in clinical trials.

    Please visit for the full U.S. Prescribing Information; the prescribing information for other countries can be found at .

    About Enhanze(TM) TechnologyEnhanze(TM) technology is a proprietary drug delivery platform using Halozyme's first approved enzyme, recombinant human hyaluronidase or rHuPH20. When formulated with other injectable drugs, Enhanze technology can facilitate the subcutaneous dispersion and absorption of these drugs. Molecules as large as 200 nanometers may pass freely through the extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin. The principal focus of Halozyme's Enhanze technology platform is the use of rHuPH20 to facilitate subcutaneous administration for large molecule biological therapeutics, some of which currently require intravenous administration.
  15. junkbond 23 september 2012 11:09
    quote:

    oudje schreef op 22 september 2012 22:26:

    Gelukkig een draai ten goede! Good luck.
    Oudje ben jij ook aandeelhouder van HALO ? Ik kocht ze toen de fda een hold op Cinryze zetten. later herstelde het aandeel. Maar ik vond het een beetje link om ze vast te houden om dat halo niet alleen dat product maar een heel platform op dat principe gebaseerd heeft. Ik dacht als dat afgeschreven wordt halveert het aandeel nog een keer. Nu de hold opgeheven is ben ik weer aandeelhouder.
  18. [verwijderd] 9 oktober 2012 10:11
    Wedbush reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO) and raised its price target to $17.00 (from $13.00).

    Halozyme Therapeutics remains in Wedbush’s BEST IDEA’S LIST, and analysts have a bullish view of the company's potential in the growing insulin pump market with the Hylenex delivery system.

    "Hylenex for insulin pumps offers several advantages to the current standard of care, including faster onset and more physiologic response," said analyst Gregory R. Wade, Ph.D.

    "Halozyme has made significant efforts towards commercialization of Hylenex for insulin pumps, we anticipate insight into timing to be the next significant catalyst for this opportunity," added Wade.

    He thinks Halozyme may begin to derive revenues from the Hylenex insulin product in the fourth quarter of 2013.

    For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

    Shares of Halozyme Therapeutics closed at $6.79 yesterday, with a 52 week range of $3.86-$13.50.

    www.streetinsider.com/Analyst+Comment...
38 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 903,61 -0,22%
EUR/USD 1,0834 +0,00%
FTSE 100 8.275,38 +0,54%
Germany40^ 18.585,90 +0,48%
Gold spot 2.327,41 0,00%
NY-Nasdaq Composite 16.735,02 -0,01%

Stijgers

VIVORY...
+19,75%
RENEWI
+2,79%
Air Fr...
+2,20%
Vastned
+2,07%
UMG
+1,89%

Dalers

JDE PE...
-4,89%
ASR Ne...
-4,88%
Corbion
-3,41%
Avantium
-2,66%
PROSUS
-2,33%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!